Ascletis Pharma (ASCLF) Stock Price, News & Analysis

Company Overview

Ascletis Pharma (OTCMKTS:ASCLF) is a clinical‐stage biopharmaceutical company headquartered in Hangzhou, China, dedicated to the research, development and commercialization of therapies for viral and liver diseases. Since its founding in 2013, the company has built an integrated platform spanning small‐molecule discovery, process chemistry and clinical development. Ascletis is listed on the Hong Kong Stock Exchange and maintains facilities for both clinical research and commercial manufacturing in Mainland China.

The company’s core pipeline focuses on direct‐acting antiviral agents targeting hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Lead assets include ASC22, an HCV NS5B polymerase inhibitor, and ASC09, an HIV‐1 protease inhibitor designed for once‐daily oral dosing. Ascletis also develops novel therapies for HBV, including nucleos(t)ide analogues and immune modulators, and has advanced preclinical candidates aimed at nonalcoholic steatohepatitis (NASH) and liver fibrosis.

In addition to its small‐molecule antivirals, Ascletis leverages traditional Chinese medicine (TCM) heritage to create proprietary formulations for liver health. Products such as Fu Zheng Hua Yu capsules combine herbal extracts with scientific validation, addressing patients in China and select Asian markets. The company engages in strategic partnerships and licensing agreements to expand the geographic reach of its marketed and clinical‐stage assets, with a focus on enhancing global access to its therapies.

Led by founder and chairman Xu Wu, Ascletis Pharma’s leadership team comprises seasoned biopharma executives with extensive experience in drug development, regulatory affairs and commercial operations. The company continues to advance its pipeline through multiple Phase 2 and Phase 3 trials, aiming to deliver innovative, safe and effective treatments for chronic viral infections and liver disorders worldwide.

Key Stats

• Today's Range: $1.54 to $1.54
• 50-Day Range: $1.25 to $1.90
• 52-Week Range: $0.16 to $1.90
• Volume: N/A
• Average Volume: 2,092 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ASCLF Stock Analysis - Frequently Asked Questions

How have ASCLF shares performed this year?

Ascletis Pharma's stock was trading at $0.2393 at the start of the year. Since then, ASCLF shares have increased by 543.5% and is now trading at $1.54.

How do I buy shares of Ascletis Pharma?

Shares of ASCLF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:ASCLF
• CIK: N/A
• Web: www.ascletis.com
• Phone: 86-571-8538-9730
• Fax: N/A
• Employees: 219
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A